SCHEMBL912656

SCHEMBL912656

COc1ccc(C(OC[C@H]2O[C@@H](n3ccc(=O)[nH]c3=O)C[C@@H]2O)(c2ccccc2)c2ccc(OC)cc2)cc1

nearest known ligand 0.60

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
DUT P33316 5/20 0.60
TYMP P19971 2/20 0.52
TYMS P04818 5/20 0.49
P2RY14 Q15391 1/20 0.42
P2RY2 P41231 1/20 0.41
P2RY4 P51582 1/20 0.41
P2RY6 Q15077 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL912657 1.00 DUT (0.60) DUTTYMPTYMSP2RY14P2RY2
SCHEMBL14403996 1.00 DUT (0.60) DUTTYMPTYMSP2RY14P2RY2
SCHEMBL19841219 1.00 DUT (0.60) DUTTYMPTYMSP2RY14P2RY2
SCHEMBL13444851 1.00 DUT (0.60) DUTTYMPTYMSP2RY14P2RY2
SCHEMBL13463839 1.00 DUT (0.60) DUTTYMPTYMSP2RY14P2RY2
SCHEMBL4422700 0.93 DUT (0.68) DUTTYMPTYMSP2RY2P2RY4
SCHEMBL3492644 0.93 DUT (0.68) DUTTYMPTYMSP2RY2P2RY4
SCHEMBL3576747 0.93 DUT (0.68) DUTTYMPTYMSP2RY2P2RY4
SCHEMBL10446526 0.93 DUT (0.68) DUTTYMPTYMSP2RY2P2RY4
SCHEMBL10446525 0.93 DUT (0.68) DUTTYMPTYMSP2RY2P2RY4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260062440-A1 Multiplex Dye Compounds LIFE TECHNOLOGIES CORP (US) 2026-03-05 US disclosed
EP-4547758-A1 MULTIPLEX DYE COMPOUNDS Life Technologies Corporation (US) 2025-05-07 EP disclosed
CN-119768474-A Multiple dye compounds 生命科技股份有限公司 2025-04-04 CN disclosed
CN-118976442-A Nucleic acid continuous synthesis device and nucleic acid continuous synthesis method thereof 张磊 2024-11-19 CN disclosed
US-12054768-B2 Methods for detecting agglutination and compositions for use in practicing the same THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2024-08-06 US disclosed
CN-117836307-A Functionalized N-acetylgalactosamine nucleosides 弘景生物科技有限公司 2024-04-05 CN disclosed
WO-2024006477-A1 MULTIPLEX DYE COMPOUNDS Life Technologies Corporation (US) 2024-01-04 WO disclosed
US-11649260-B2 Functionalized N-acetylgalactosamine nucleosides HONGENE BIOTECH CORPORATION (US) 2023-05-16 US disclosed
US-20230034284-A1 FUNCTIONALIZED N-ACETYLGALACTOSAMINE NUCLEOSIDES HONGENE BIOTECH CORPORATION 2023-02-02 US disclosed
EP-4123031-A1 METHODS FOR DETECTING AGGLUTINATION AND COMPOSITIONS FOR USE IN PRACTICING THE SAME The Regents of The University of California (US) 2023-01-25 EP disclosed
EP-1308452-B1 Oligonucleotide labeling reactants based on acyclonucleosides and conjugates derived thereof WALLAC OY (FI) 2008-03-19 EP disclosed
US-7282581-B2 Oligonucleotide labeling reactants based on acyclonucleosides and conjugates derived thereof WALLAC OY (FI) 2007-10-16 US disclosed
EP-1701727-A1 DUTPASE INHIBITORS Medivir Aktiebolag (SE) 2006-09-20 EP disclosed
US-6949639-B1 Oligonucleotide labeling reactants and their use WALLAC OY (FI) 2005-09-27 US disclosed
WO-2005085861-A2 NUCLEIC ACIDS AND ENCODED POLYPEPTIDES FOR USE IN LIVER DISORDERS AND EPITHELIAL CANCER ORIDIS BIOMED FORSCHUNGS- UND ENTWICKLUNGS GMBH (AT) 2005-09-15 WO disclosed
WO-2005065689-A1 DUTPASE INHIBITORS MEDIVIR AB (SE) 2005-07-21 WO disclosed
US-20040260080-A1 Oligonucleotide labeling reactants and their use HOVINEN JARI (FI) 2004-12-23 US disclosed
US-20030118999-A1 Oligonucleotide labeling reactants based on acyclonucleosides and conjugates derived thereof WALLAC OY (FI) 2003-06-26 US disclosed
EP-1308452-A2 Oligonucleotide labeling reactants based on acyclonucleosides and conjugates derived thereof WALLAC OY (FI) 2003-05-07 EP disclosed
EP-1152010-A2 Oligonucleotide labeling reactants and their use WALLAC OY (FI) 2001-11-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260062440-A1 Multiplex Dye Compounds CCR7, NSUN2, SLC43A1 DUT 391/4885TYMP 1231/4885TYMS 775/4885
US-20040260080-A1 Oligonucleotide labeling reactants and their use SSU72, LIG4, NSUN2 DUT 15/4885TYMP 1443/4885TYMS 867/4885
US-20030118999-A1 Oligonucleotide labeling reactants based on acyclonucleosides and conjugates derived thereof PCNA, DUT, POLL DUT 2/4885TYMP 79/4885TYMS 107/4885
US-11649260-B2 Functionalized N-acetylgalactosamine nucleosides FUT6, B3GNT2, GALNT6 DUT 39/4885TYMP 69/4885TYMS 95/4885
US-20230034284-A1 FUNCTIONALIZED N-ACETYLGALACTOSAMINE NUCLEOSIDES FUT6, B3GNT2, GALNT6 DUT 39/4885TYMP 69/4885TYMS 95/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.